$1.5M
Pre-Seed Ask
26 wks
Week Roadmap
49
Funding Sources
9
High Priority
Company Snapshot
- Tagline
- The AI HealthOS for Every Body
- Round
- Pre-Seed — SAFE / Priced Equity
- Ask
- $1.5M
- Use of funds
- FDA De Novo + 3 Enterprise Pilots
- Series A trigger
- FDA Clearance → $12–18M (Q4 2027)
- Year 5 ARR
- $27.5M (175% CAGR) — $42M target
- Accelerators
- Stanford StartX · Techstars Anywhere 2026
- IP
- Stanford SleepFM License + 3 Patents Pending · MARD 11.2%
- Regulatory
- FDA De Novo Pathway (Novel Device) · EU MDR CE-mark
- Credibility
- Nature Medicine validation (Jan 2026, Stanford, Thapa et al.)
- Team
- UK-anchored · distributed across UK, Germany & Italy · women-led
- Contact
- eangelica@tapas.one
Use of Funds
Product Development35%
Nano-cream formulation, AI platform, mobile app
Clinical Validation25%
FDA pathway, EU MDR, clinical trials
Sales & Marketing20%
UK/EU/US market entry, partnerships
Operations & Team12%
Key hires, infrastructure, CS team
Legal & IP8%
Patent portfolio, regulatory filings
Strategic Insights
- EU programmes are NOT mutually exclusive — apply to multiple streams in parallel.
- EIC Accelerator is the highest-probability fast cash (up to €2.5M non-dilutive + equity option).
- Innovate UK is second-fastest (£150k–£250k) if you have a UK legal entity.
- Bertelsmann ($200M fund), SwissHealth, and CDP (Italy) are immediate VC conversations — reach out this week.
- Feature the Nature Medicine validation (Jan 2026, Stanford, Thapa et al.) prominently in every submission.
- Leverage the UK/Germany/Italy cross-border team — EU programmes prioritise cross-border collaboration.
Key Links
Next Deadlines
SLINGSHOT 2026
🇸🇬 Southeast Asia · Prize + exposure
30 Jun 2026
EIC Accelerator — short proposal (cut-off 1)
🇪🇺 EU (UK eligible for grant) · Non-dilutive grant + equity
08 Jul 2026
EIC Pathfinder Challenges — OPENS
🇪🇺 EU · Non-dilutive grant
28 Jul 2026
Crick KQ Labs Accelerator
🇬🇧 UK (London) · Programme
28 Aug 2026
EIC Accelerator — full proposal (cut-off 2)
🇪🇺 EU (UK eligible for grant) · Non-dilutive grant + equity
02 Sep 2026